

### A Unitary View on the Aetiology of Schizophrenia

SIR: The article by Wexler (*Journal*, April 1986, 148, 357–362) is interesting and thought provoking. It reminds one of the theory of neural plasticity and shows that brain function is dynamic rather than static. I had earlier formulated a hypothesis on the aetiology of schizophrenia, attempting to explain the conflicting findings in schizophrenic research.

Some individuals are genetically determined to have weak and vulnerable dopaminergic systems. When subjected to stresses, part of the dopaminergic pathway ceases to function. To compensate for the loss, the surviving dopaminergic fibres give off additional nerve terminals and D2 receptors. This overreaction gives rise to a relative increase in dopaminergic activity and manifests as the positive symptoms of schizophrenia. In mild cases, the dysfunction is self limiting and dopaminergic transmission is able to restore to its previous level of functioning, and the process is completed. The psychotic episode is thus named a schizophreniform reaction.

In more severe cases, the dysfunction is more chronic and progressive. It results in actual degeneration of the dopaminergic pathways. These degenerative changes are supported by the CT scan studies, postmortem findings, as well as the regional difference in cerebral blood flow and PET studies. The significant reduction of CCK (hippocampus, amygdala), somatostatin (hippocampus), opiate receptors (caudate nucleus), 5 HT receptors (frontal cortex), angiotensin converting enzymes (globus pallidus and substantia nigra) and GABA (nucleus accumbens) also point to this degenerative shrinkage involving certain parts of the brain. Postmortem findings indicated subependymal gliosis in the diencephalon and hypothalamus in chronic schizophrenia. This is consistent with the CT scan evidence of a moderate enlargement of the third and lateral ventricles reported in approximately half of the chronic patients. Gliosis is usually a response to brain injury. The origin of this gliosis may lie at the midbrain ventral tegmental area where the dopaminergic neurones originate. The A10 group of the ventral tegmental area spreads along the mesolimbic and mesocortical pathways to end at the limbic structures and pre-frontal area. Because the DA content in the pre-frontal cortex is only approximately 1% of the DA concentration in the striatum, pathological evidence of cell loss or gliosis in this area may not be obvious. However, cerebral blood flow and PET studies do reveal the frontal region abnormalities.

Negative symptoms seem to result when the degeneration becomes more extensive and when the mesocortical dopamine system is involved. As the

effect of DA antagonist in this system is greatly diminished, the symptoms are irreversible with neuroleptic drugs. It may actually become more prominent when the positive symptoms are under control.

Cerebral lateralisation studies have established the asymmetric distribution of major neurotransmitters in the human brain. Dopaminergic systems are left hemisphere biased. It can be deduced that lesions of the dopaminergic system are reflected as left hemisphere dysfunction and such are found in the CT scan, regional blood flow, PET and EEG studies, as well as a specific increase of dopamine in the left hemisphere.

The reactive compensatory process may not be neurotransmitter specific. Hence an alternation in production of noradrenalin may occur in response to dopamine system degeneration, giving rise to affective symptoms which sometimes occur simultaneously or following schizophrenic systems.

C. W. LO

*Kowloon Hospital Psychiatric Unit  
147A, Argyle Street  
Kowloon, Hong Kong*

### References

- BANNON, M. J. & ROTH, R. H. (1983) Pharmacology of mesocortical dopamine neurones. *Pharmacological Review*, **35**, 53–68.  
GLICK, S. D., ROSS, A. R. & HOUGH, L. B. (1982) Lateral asymmetry of neurotransmitters in human brain. *Brain Research*, **234**, 53–63.  
HARACZ, J. L. (1985) Neural plasticity in schizophrenia. *Schizophrenia Bulletin*, **11**, 191–229.  
STEVENS, J. R. (1982) Neuropathology of schizophrenia. *Archives of General Psychiatry*, **39**, 1131–1139.

### Endogenous Subtype of Depression

SIR: I read with interest the Young *et al* article (*Journal*, March 1986, 148, 257–267).

Their conclusion rests on their use of the SADS. They interpret SADS item 326 as addressing anhedonia. Rather, this item addresses loss of interest or pleasure. Thus, someone who had lost interest in all activities but nonetheless could still enjoy some activities when actively involved in them would be rated 6 on this item. Thus, this is not strictly a loss of pleasure item and neither anhedonia nor DSM-III melancholia can therefore be accurately inferred.

From a theoretical point of view, Klein (1974) has hypothesized that pervasive anhedonia is the underlying hallmark of melancholia, in contradistinction to decreased interest in activities with retained ability to experience pleasure. From a practical standpoint, many patients report significant and often pervasive loss of interest in activities but still retain the ability to enjoy them once involved. SADS does not allow

for making this distinction, and I believe that collaborative study interviewers did not add additional questions to their interview to cover this distinction. If not, it is then impossible for the authors of this article to convert their SADS interview into a DSM-III diagnosis or to derive a sub-type characterized by pervasive anhedonia.

I submit that perhaps they have identified one group which has pervasive loss of interest without the traditional vegetative signs of depression while another group has pervasive loss of pleasure plus the neuro-vegetative signs, as has already been hypothesized by Klein.

It seems logically impossible for a patient to meet DSM-III criteria for melancholia without meeting at least probable criteria for RDC endogenous depression. Thus, it appears to be a mistake to report 14 patients with DSM-III melancholia who did not also have at least probable RDC endogenous depression.

JONATHAN W. STEWART

Office of Mental Health  
New York State Psychiatric Institute  
722 West 168th Street  
New York 10032

#### Reference

KLEIN, D. F. (1974) Endogenomorphic depression. *Archives of General Psychiatry*, **31**, 447-454.

#### Reliability of the SRQ-20

SIR: We were interested to read the paper by Drs Mari & Williams (*Journal*, January, 1986, **148**, 23-26). We used the SRQ-20 as a screening instrument among in-patients of a general medicine ward at the AIIMS over a six-month period. Using 11 as the cut-off point, we examined (using the ninth edition of the Present State Examination and a detailed psychiatric history) all those scoring 11 or above as well as a systematic sub-sample of those scoring below 10.

Out of a total of 326 administered the SRQ-20, 158 were examined and diagnosis was made on the basis of ICD-9. At the end of the study, specificity and sensitivity were determined at each possible cut-off point from 1 to 20, based on the 42 psychiatric cases and 116 non-cases. A correction factor was applied so as to generalise the results to the whole sample using the method suggested by Goldberg (1978).

We found great divergence between specificity and sensitivity. The original cut-off score of 11 had a sensitivity of 46.6%, and specificity of 74.1%. At 7/8, these were, respectively, 77.4% and 66.6% (sensitivity) and 51.1% and 54.4% (specificity). We found 9

the ideal cut-off, where sensitivity was 62.9% and specificity 62%. Females, and those educated at school level (matric) or less, scored significantly higher ( $P < 0.05$  and  $P < 0.01$  respectively, using the chi-squared test). The mean score for the total population was also high—7.78 (SD  $\pm$  4.95).

We feel, therefore, that the SRQ-20 may need considerable modification for use in known physically ill samples. Weighting certain questions, skewing questions toward the more "psychological", changing "false positive" questions, and defining the duration or severity of symptoms, may all have to be considered.

SMITA L. NIMGAONKAR  
K. R. SUNDARAM  
N. N. WIG

All India Institute of Medical Sciences  
New Delhi 110029  
India

#### References

- GOLDBERG, D. (1978) *Manual of the General Health Questionnaire*. Windsor, Berks. NFER, Nelson Publishing Company.  
HARDING, T. W., CLIMENT, C. E., GIEL, R., IBRAHIM, H. H. A., SRINIVASA-MURTHY, R., SULEIMAN, M. A. & WIG, N. N. (1983) The WHO collaborative study of strategies for extending mental health care. II. The development of new research methods. *American Journal of Psychiatry*, **140**, 1474-1480.  
WING, J. K., BEBBINGTON, P. & ROBINS, L. N. (eds) (1981) *What is a Case? The Problem of Definition in Psychiatric Community Surveys*. London: Grant McIntyre.

#### Monoamine Oxidase Inhibitors

SIR: Professor Blackwell's warning (*Journal*, February, 1986, **143**, 216-217) about the danger of minimising the risk of MAO inhibition is welcome, if only as the basis for informed discussion. However, as he will no doubt recall (Samuel & Blackwell, 1968), he himself was not always on the side of the angels.

At Bethlem Royal Hospital, the reaction to Rowe's initial observation, shared by Professor Blackwell, was one of ridicule, while my suggestion that Rowe's observation be taken seriously was treated with contempt. My persistence in pursuing the matter was encouraged only by Professor Linford Rees. It is to the credit of neither of us that this encouragement has never been recorded by Blackwell in any of his many publications, nor in the publication of which I was a joint author (Samuel & Blackwell, 1968). This letter will be the first time in the 23 years since this not altogether unimportant discovery was made, that Professor Rees' essential contribution will have been acknowledged in print. It was my pleasure, in 1983, finally to speak to Rowe. To my astonishment he was totally ignorant of the